de la Fuente Macarena I, Haggiagi Aya, Moul Adrienne, Young Robert J, Sidani Charif, Markoe Arnold, Vega Francisco, DeAngelis Lisa M, Lossos Izidore S
a Departments of Neurology and Sylvester Comprehensive Cancer Center , University of Miami , Miami , FL , USA.
b Department of Neurology , Memorial Sloan Kettering Cancer Center , New York , NY , USA.
Leuk Lymphoma. 2017 Apr;58(4):882-888. doi: 10.1080/10428194.2016.1218006. Epub 2016 Sep 21.
Dural lymphoma (DL) is a rare type of primary CNS lymphoma arising from the dura mater. The optimal treatment is uncertain. A retrospective review was performed on 26 DL patients. Seventeen patients underwent resection and nine had a biopsy. Twenty three patients could be assessed for a response to treatment after surgery. Thirteen received focal radiotherapy (RT), six whole brain RT (WBRT), three chemotherapy alone and one chemotherapy followed by WBRT. Twenty two achieved complete response (CR) and one a partial response (PR). Four patients relapsed (two local and two systemic). Median follow up was 64 months, with median progression free survival (PFS) and OS not reached. Three year PFS was 89% (95% CI 0.64-0.97). All patients are alive at last follow-up, demonstrating that DL is an indolent tumor with long survival. CR is achievable with focal therapy in the majority of cases, but there is a risk for relapses and long-term follow-up is recommended.
硬脑膜淋巴瘤（DL）是一种罕见的起源于硬脑膜的原发性中枢神经系统淋巴瘤。最佳治疗方案尚不确定。对26例DL患者进行了回顾性研究。17例患者接受了切除术，9例进行了活检。23例患者术后可评估对治疗的反应。13例接受了局部放疗（RT），6例接受了全脑放疗（WBRT），3例仅接受化疗，1例接受化疗后行WBRT。22例达到完全缓解（CR），1例部分缓解（PR）。4例患者复发（2例局部复发，2例全身复发）。中位随访时间为64个月，中位无进展生存期（PFS）和总生存期（OS）未达到。三年PFS为89%（95%CI 0.64 - 0.97）。在最后一次随访时所有患者均存活，表明DL是一种惰性肿瘤，生存期长。大多数病例通过局部治疗可实现CR，但存在复发风险，建议进行长期随访。
